Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Tildrakizumab Market Research Report 2026: $3+ Bn Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F

globenewswire.com
SUN Sun Pharma received approval for its tildrakizumab injection in China, indicating positive market reception and expansion for its treatment of plaque psoriasis. PFE Pfizer is mentioned as a key player in the tildrakizumab market, suggesting its involvement in a growing sector, but no specific company-driven news is provided. LLY Eli Lilly is identified as a market dominator in the tildrakizumab space, indicating its significant presence in a growing therapeutic area. BMY Bristol Myers Squibb is listed as one of the dominant companies in the tildrakizumab market, suggesting its participation in a growing sector.

Tildrakizumab Market Research Report 2026: $3+ Bn Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F Dublin, May 11, 2026 (GLOBE NEWSWIRE) -- The "Tildrakizumab Market Report 2026" has been added to ResearchAndMarkets.com's offering.

The tildrakizumab market has seen substantial growth, projected to expand from $1.76 billion in 2025 to $1.96 billion in 2026, at a CAGR of 11.7%.By 2030, the market is expected to reach $3.02 billion, maintaining a CAGR of 11.4%.

The Tildrakizumab Market Global Report 2026 is an essential resource for strategists, marketers, and senior management, offering valuable insights into the rapidly growing tildrakizumab market. This comprehensive report highlights key trends that will influence the market over the next decade, offering a robust analysis that can guide strategic decision-making.

The primary drivers of this growth include the increasing prevalence of plaque psoriasis, clinical validation of biologic efficacy, the proliferation of specialty dermatology clinics, rising acceptance of injectable biologics, and improved reimbursement frameworks. Factors fueling this growth encompass a higher demand for personalized autoimmune therapies, augmented biologic indications, focus on long-term disease management, home-based biologic administration adoption, and rising investments in immunology research.

Autoimmune diseases are on the rise due to environmental factors such as pollution, elevating the demand for treatments like tildrakizumab, which targets the IL-23 pathway. Data from Public Health Scotland highlighted a rise in newly diagnosed MS patients, underlining the market's growth potential. Enhanced healthcare facilities are pivotal in supporting market expansion by improving patient access to advanced treatments and ensuring better healthcare provider awareness, as seen in the increase of hospitals reported by the American Hospital Association.

Innovative formulations are key focus areas for market leaders like Sun Pharmaceutical Industries Ltd., which gained approval from the Chinese NMPA for its tildrakizumab injection in treating plaque psoriasis. These advancements target IL-23, thereby reducing inflammation and symptom severity. The market is dominated by players such as Almirall S.A., Novartis, Pfizer, Eli Lilly, and Bristol Myers Squibb, among others.

Geographically, North America led the market in 2025, while Asia-Pacific is expected to be the fastest-growing region. The countries covered in this market analysis include Australia, Brazil, China, and more, each contributing to the broader regional dynamics in the market.

Key Attributes:

Report Scope:

Markets Covered:

Subsegments:

Companies Featured

For more information about this report visit https://www.researchandmarkets.com/r/p8wxoh

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.